Harbour BioMed and Kelun-Biotech Announce NMPA Approval of IND Application for HBM7575/SKB575 for the Treatment of Asthma

RegulatoryapprovedHBM7575/SKB575Positive

AI Analysis

Summary

Harbour BioMed and Kelun-Biotech announced NMPA approval of the IND application for HBM7575/SKB575, an antibody therapeutic candidate for asthma treatment, enabling clinical development to proceed in China.

Outcome Details

NMPA approval of IND application

Importance:5/10

Sentiment:

0.75

NMPAIND approvalAsthmaAntibody therapeuticsImmunology

Related Companies

$DFPH $GBCYD

Read the original article

Published by PR Newswire Clinical Trials on July 15, 2026 10:01 AM

Read Original